Prothena Corporation reported its second quarter 2026 financial results, posting a net loss of $18.6 million and updating its year-end cash guidance to approximately $259 million at the midpoint. The company had $289.1 million in cash, cash equivalents and restricted cash as of June 30, 2026, and no debt. The updated cash guidance reflects shares repurchased through July 30, 2026, under its up to $100 million share repurchase program. Prothena also highlighted the publication of Phase 2b PADOVA trial results for prasinezumab in The Lancet and ongoing Phase 3 trials by partners Roche and Novo Nordisk, with potential aggregate future milestone payments of up to approximately $3 billion plus royalties.
Prothena Corporation plcNet loss and updated cash guidance reflect share repurchases, reducing cash.
Novo Nordisk A/SOngoing Phase 3 trials by partner Novo Nordisk.
Roche Holding AGPhase 2b results published and ongoing Phase 3 trials by partner Roche.
